Haemophilia A
Haemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII, leading to prolonged bleeding after injuries or surgery and spontaneous bleeding episodes.
Severe Hemophilia A: Continued Access to Efanesoctocog Alfa
We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Have you completed one of the required parent studies: Sobi.BIVV001-001, Sobi.BIVV001-003, or LTS16294?
- Do you have a positive inhibitor result (≥0.6 Bethesda units/mL) from a recent test?
- Are you currently participating in any other clinical study?
- Are you able to follow study procedures and complete a patient diary throughout the study?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
University Multiprofile Hospital For Active Treatment Saint Georgi EAD
Clinical Hematology Clinic
Plovdiv, Bulgaria
Specialized Hospital For Active Treatment Of Hematological Diseases EAD
Third Department of Clinical Hematology at Clinical Hematology Clinic
Sofia, Bulgaria
Centre Hospitalier Universitaire De Bordeaux
Site Hôpital des Enfants, Competence and Resources Center for Constitutional Hemorrhagic Disorders
Bordeaux, France
Sponsor: Swedish Orphan Biovitrum AB (publ)
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.